Bulletin physiology and pathology of respiration,
Journal Year:
2022,
Volume and Issue:
1(86), P. 138 - 148
Published: Dec. 23, 2022
The
review
considers
the
main
groups
of
drugs
used
to
treat
bronchial
asthma
depending
on
severity
disease.
mechanisms
action
and
effectiveness
taking
anti-asthma
drugs,
their
combinations
side
effects
are
covered
in
detail.
Particular
attention
is
paid
targeted
therapy
with
biological
which
aimed
at
reducing
allergic
inflammatory
response
patients
severe
asthma.
This
approach
allows
change
natural
course
disease,
reduce
airway
inflammation
without
associated
glucocorticosteroids.
current
available
drug
therapies
may
be
useful
clinicians
selecting
appropriate
strategies
for
treatment.
International Journal of Infectious Diseases,
Journal Year:
2022,
Volume and Issue:
122, P. 332 - 336
Published: June 14, 2022
The
COVID-19
pandemic
continues,
and
the
death
toll
continues
to
surge.
This
systematic
review
meta-analysis
aimed
determine
efficacy
of
therapeutic
plasma
exchange
(TPE)
on
mortality
in
patients
with
COVID-19.A
search
was
made
PubMed,
Embase,
Cochrane
Library,
clinicaltrials.gov,
without
language
restrictions.
Controlled
clinical
trials
treatment
TPE,
compared
standard
care,
were
reviewed.
Studies
pooled
according
risk
ratios
(RRs)
weighted
mean
differences,
95%
confidence
intervals
(CIs).A
total
six
(enrolling
343
participants)
met
inclusion
criteria.
Therapeutic
showed
significant
effect
(RR
0.41,
CI
0.24
0.69;
P
=
0.0008).TPE
significantly
reduced
hospitalized
moderate-to-critical
COVID-19.
Plasma
therapy
should
be
considered
for
Reviews in Medical Virology,
Journal Year:
2023,
Volume and Issue:
33(2)
Published: Jan. 4, 2023
The
Coronavirus
disease-2019
(COVID-19)
pandemic
continues,
and
the
death
toll
continues
to
surge.
This
meta-analysis
aimed
determine
efficacy
of
anakinra
on
mortality
in
patients
with
COVID-19.
A
systematic
search
was
made
PubMed,
Embase,
Cochrane
Library,
clinicaltrials.gov,
without
language
restrictions.
Randomized
controlled
trials
treatment
COVID-19
anakinra,
compared
placebo
or
blank,
were
reviewed.
Studies
pooled
risk
ratios
(RRs),
95%
confidence
intervals
(CIs).
Five
(enrolling
1859
participants)
met
inclusion
criteria.
There
no
statistically
significant
difference
14-day
(RR
0.78,
CI
0.43-1.39;
P
=
0.40),
28-day
1.06,
0.89-1.26;
0.51),
90-day
1.01,
0.73-1.39;
0.97)
between
two
groups.
Sensitivity
analyses
further
confirmed
these
results.
Anakinra
not
associated
reduced
hospitalised
probably
should
be
used
routinely
patients.
Clinical Cardiology,
Journal Year:
2022,
Volume and Issue:
45(10), P. 995 - 1001
Published: Aug. 2, 2022
Abstract
Considering
the
prevalence
of
dyspnea
in
acute
heart
failure
(AHF),
its
reduction
is
important
to
both
patients
and
caregivers.
This
meta‐analysis
was
performed
determine
efficacy
safety
tolvaptan
on
early
relief
with
AHF.
A
systematic
search
made
PubMed,
Embase,
Web
Science,
Cochrane
Library,
clinicaltrials.gov
,
without
language
restrictions.
Randomized
controlled
trials
(RCTs)
treatment
AHF
tolvaptan,
compared
placebo
or
blank,
were
reviewed.
Studies
pooled
relative
risk
(RR),
95%
confidence
interval
(CI).
Five
RCTs
(enrolling
4857
participants)
met
inclusion
criteria.
Tolvaptan
presented
significant
effects
12
h
(RR:
1.98;
CI:
1.24−3.15;
p
=
.004),
24
h/day
1
1.15;
1.07−1.24;
.0003),
48
1.20;
1.06−1.36;
72
1.18;
1.02−1.37;
.03).
No
increase
noticed
incidence
worsening
renal
function
group
1.10;
0.87−1.39;
.43).
significantly
improved
patient‐assessed
persistently
Complementary Therapies in Medicine,
Journal Year:
2022,
Volume and Issue:
72, P. 102907 - 102907
Published: Dec. 10, 2022
The
Coronavirus
disease-2019
(COVID-19)
pandemic
continues,
and
the
death
toll
continues
to
surge.
Ozone
therapy
has
long
been
used
in
treatment
of
a
variety
infectious
diseases,
probably
through
its
antioxidant
properties
supply
oxygen
hypoxic
tissues.
This
systematic
review
meta-analysis
aimed
determine
efficacy
ozone
on
mortality
patients
with
COVID-19.A
search
was
made
PubMed,
Embase,
Cochrane
Library,
clinicaltrials.gov,
without
language
restrictions.
Prospective
controlled
trials
COVID-19
ozone,
compared
placebo
or
blank,
were
reviewed.
Studies
pooled
risk
ratios
(RRs)
weighted
mean
differences
(WMDs),
95%
confidence
intervals
(CIs).Eight
(enrolling
371
participants)
met
inclusion
criteria.
showed
significant
effects
(RR
0.38,
CI
0.17-0.85;
P
=
0.02),
length
hospital
stay
(WMD
-1.63
days,
-3.05
-0.22
days;
polymerase
chain
reaction
(PCR)
positivity
0.07,
0.01-0.34;
0.001).Ozone
significantly
reduced
mortality,
PCR
positivity,
hospitalized
COVID-19.
should
be
considered
for
patients.
European Journal of Clinical Investigation,
Journal Year:
2023,
Volume and Issue:
53(11)
Published: July 1, 2023
Abstract
Background
Macitentan
has
demonstrated
its
effectiveness
in
patients
with
pulmonary
hypertension
(PH),
but
safety,
especially
for
long‐term
use,
needs
to
be
further
explored.
This
systematic
review
and
meta‐analysis
aimed
determine
the
safety
of
use
macitentan
PH.
Methods
A
search
was
made
PubMed,
Embase,
Cochrane
Library
clinicaltrials.gov
,
without
language
restrictions.
Randomised
controlled
trials
(RCTs)
on
treatment
PH
macitentan,
compared
placebo,
were
reviewed.
Estimated
effects
included
studies
pooled
as
risk
ratios
(RRs),
95%
confidence
intervals
(CIs).
Results
Six
RCTs
(enrolling
1003
participants)
met
inclusion
criteria.
Anaemia
(RR
3.86,
CI
2.05–7.30),
headache
1.52,
1.02–2.26)
bronchitis
2.24,
1.30–3.87)
more
frequent
groups.
There
no
statistically
significant
difference
proportion
at
least
one
adverse
event
(AE)
or
serious
(SAE),
AEs
leading
discontinuation
study
treatment,
all‐cause
death,
right
ventricular
failure
(RVF)
peripheral
oedema
between
two
Conclusions
The
is
safe
PH,
although
a
higher
anaemia,
bronchitis.
Journal of Investigative Medicine,
Journal Year:
2024,
Volume and Issue:
72(6), P. 567 - 573
Published: May 15, 2024
This
systematic
review
and
meta-analysis
aimed
to
determine
the
efficacy
of
inhaled
corticosteroids
(ICS)
on
mortality
in
patients
with
coronavirus
disease-2019
(COVID-19).
A
search
was
made
PubMed,
Embase,
Cochrane
Library,
clinicaltrials.gov,
without
language
restrictions.
Randomized
controlled
trials
(RCTs)
treatment
COVID-19
ICS
were
reviewed.
Studies
pooled
risk
ratios
(RRs),
95%
confidence
intervals
(CIs).
Eleven
RCTs
(enrolling
5832
participants)
met
inclusion
criteria.
There
no
statistically
significant
difference
COVID-19-related
death
(RR
0.88,
CI
0.38–2.04),
all-cause
1.05,
0.49–2.23),
invasive
ventilation
1.26,
0.60–2.62)
between
two
groups.
not
associated
reduced
COVID-19.
